{"organizations": [], "uuid": "3c76a599f09d43c5f050f651844071581b5abc79", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180419.html", "section_title": "Archive News &amp; Video for Thursday, 19 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/novartis-results/novartis-q1-sales-beat-gets-help-from-weak-dollar-idUSFWN1RV11R", "country": "US", "domain_rank": 408, "title": "Novartis Q1 sales beat gets help from weak dollar", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-19T13:16:00.000+03:00", "replies_count": 0, "uuid": "3c76a599f09d43c5f050f651844071581b5abc79"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/novartis-results/novartis-q1-sales-beat-gets-help-from-weak-dollar-idUSFWN1RV11R", "ord_in_thread": 0, "title": "Novartis Q1 sales beat gets help from weak dollar", "locations": [], "entities": {"persons": [{"name": "john revill", "sentiment": "none"}, {"name": "john miller", "sentiment": "none"}, {"name": "vas narasimhan", "sentiment": "none"}], "locations": [{"name": "zurich", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "novartis", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ZURICH, April 19 (Reuters) - Swiss drugmaker Novartis posted a 10 percent rise in first-quarter sales, more than analysts expected, as new Chief Executive Officer Vas Narasimhan got a boost from a weaker U.S. dollar and rising revenue from new medicines.\nCore net income was $2.98 billion, the Basel-based company said in a statement on Thursday, equalling the average analyst forecast in a Reuters poll. Sales rose to $12.7 billion, compared to analyst forecasts that averaged $12.3 billion.\nIn constant currencies, sales rose 4 percent, Novartis said. (Reporting by John Miller, editing by John Revill)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-19T13:16:00.000+03:00", "crawled": "2018-04-20T11:46:12.009+03:00", "highlightTitle": ""}